KR20180013797A - Vinegar with enhanced anti-obesity, anti-inflammatory and skin whitening effect using Mapleleaf ainsliaea and manufacturing method thereof - Google Patents
Vinegar with enhanced anti-obesity, anti-inflammatory and skin whitening effect using Mapleleaf ainsliaea and manufacturing method thereof Download PDFInfo
- Publication number
- KR20180013797A KR20180013797A KR1020170096093A KR20170096093A KR20180013797A KR 20180013797 A KR20180013797 A KR 20180013797A KR 1020170096093 A KR1020170096093 A KR 1020170096093A KR 20170096093 A KR20170096093 A KR 20170096093A KR 20180013797 A KR20180013797 A KR 20180013797A
- Authority
- KR
- South Korea
- Prior art keywords
- vinegar
- obesity
- acetic acid
- inflammatory
- skin whitening
- Prior art date
Links
- 239000000052 vinegar Substances 0.000 title claims abstract description 62
- 235000021419 vinegar Nutrition 0.000 title claims abstract description 62
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 29
- 230000003579 anti-obesity Effects 0.000 title claims abstract description 20
- 230000002087 whitening effect Effects 0.000 title claims abstract description 20
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 15
- 241000132064 Ainsliaea Species 0.000 title description 2
- 241000510091 Quadrula quadrula Species 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 99
- 239000000284 extract Substances 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000002904 solvent Substances 0.000 claims abstract description 6
- 230000032683 aging Effects 0.000 claims abstract description 5
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 238000005406 washing Methods 0.000 claims abstract description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 22
- 235000013376 functional food Nutrition 0.000 claims description 20
- 230000036541 health Effects 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 17
- 206010061218 Inflammation Diseases 0.000 claims description 15
- 230000004054 inflammatory process Effects 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 10
- 230000008099 melanin synthesis Effects 0.000 claims description 10
- 208000008589 Obesity Diseases 0.000 claims description 9
- 235000020824 obesity Nutrition 0.000 claims description 9
- 239000000049 pigment Substances 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 5
- 208000021710 Hyperpigmentation disease Diseases 0.000 claims description 5
- 241000589234 Acetobacter sp. Species 0.000 claims description 4
- 230000004132 lipogenesis Effects 0.000 claims description 4
- 241000132081 Ainsliaea acerifolia Species 0.000 abstract 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 30
- 230000000694 effects Effects 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 13
- 238000000855 fermentation Methods 0.000 description 12
- 230000004151 fermentation Effects 0.000 description 12
- 239000000469 ethanolic extract Substances 0.000 description 10
- 235000013305 food Nutrition 0.000 description 9
- 102000003425 Tyrosinase Human genes 0.000 description 8
- 108060008724 Tyrosinase Proteins 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 108010051081 dopachrome isomerase Proteins 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 210000002752 melanocyte Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 206010003210 Arteriosclerosis Diseases 0.000 description 5
- 208000012641 Pigmentation disease Diseases 0.000 description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 208000003351 Melanosis Diseases 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 4
- 102000003945 NF-kappa B Human genes 0.000 description 4
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 108010014402 tyrosinase-related protein-1 Proteins 0.000 description 4
- YFTGOBNOJKXZJC-UHFFFAOYSA-N 5,6-dihydroxyindole-2-carboxylic acid Chemical compound OC1=C(O)C=C2NC(C(=O)O)=CC2=C1 YFTGOBNOJKXZJC-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010016952 Food poisoning Diseases 0.000 description 3
- 208000019331 Foodborne disease Diseases 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 3
- 101710200814 Melanotropin alpha Proteins 0.000 description 3
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 235000011194 food seasoning agent Nutrition 0.000 description 3
- 208000000069 hyperpigmentation Diseases 0.000 description 3
- 230000003810 hyperpigmentation Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010008570 Chloasma Diseases 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 101150053046 MYD88 gene Proteins 0.000 description 2
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 241000256259 Noctuidae Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 2
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000002780 melanosome Anatomy 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 108091008743 testicular receptors 4 Proteins 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 101000605172 Aspergillus niger (strain CBS 513.88 / FGSC A1513) Probable endopolygalacturonase E Proteins 0.000 description 1
- 101000605171 Aspergillus niger Endopolygalacturonase E Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 101000941281 Bos taurus Gastric triacylglycerol lipase Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101001031598 Dictyostelium discoideum Probable serine/threonine-protein kinase fhkC Proteins 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 229920003266 Leaf® Polymers 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 1
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 1
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 1
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102100036201 Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial Human genes 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- CDXSJGDDABYYJV-UHFFFAOYSA-N acetic acid;ethanol Chemical compound CCO.CC(O)=O CDXSJGDDABYYJV-UHFFFAOYSA-N 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000008687 biosynthesis inhibition Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000009920 food preservation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000003520 lipogenic effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 238000009343 monoculture Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12J—VINEGAR; PREPARATION OR PURIFICATION THEREOF
- C12J1/00—Vinegar; Preparation or purification thereof
- C12J1/04—Vinegar; Preparation or purification thereof from alcohol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 단풍취를 이용한 항비만, 항염증 및 피부 미백 효능이 증진된 식초 및 그 제조방법에 관한 것이다. The present invention relates to a vinegar having improved anti-obesity, anti-inflammatory and skin whitening efficacy using a single-pest, and a preparation method thereof.
식초는 전통적으로 동서양을 막론하고 오랜 역사를 지닌 발효 식품으로 간장, 된장과 함께 우리 식생활과 밀접한 관련을 맺고 있는 중요한 조미료의 하나이다. 식초는 미생물을 이용하여 당류나 전분질을 함유하고 있는 여러 원료를 알코올 발효한 후 초산 발효하여 제조하는 원리이며, 신맛을 내는 초산성분을 비롯하여 25여 종의 유기산과 20여 종의 아미노산, 20여 종의 에테르 및 각종 영양물질이 함유된 복합 산미 조미료이자 건강식품이라 할 수 있다.Vinegar is traditionally a fermented food with a long history, both east and west, and it is one of the important seasonings that is closely related to our diet along with soy sauce and miso. Vinegar is the principle of fermentation of various raw materials containing saccharides and starches by fermentation with alcohol and then fermenting it with acetic acid. It contains 25 kinds of organic acids, 20 kinds of amino acids, 20 kinds Ether and a variety of nutrients containing a complex acidic seasoning and health food can be said.
식초는 식품 보존 효과뿐만 아니라 식품 방향제 또는 치료제로 널리 사용되고 있다. 일반적으로 식초는 음식물 자체의 맛을 좋게 할 뿐 아니라 짠맛을 덜어주고 지방을 중화시켜 주는 작용을 한다. 또한, 식초는 피를 맑게 하며 피로 회복에 효과가 크고 각종 성인병을 치료하는데 좋은 원료로 널리 알려져 있다. 또한, 식초에 함유되어 있는 유기산과 아미노산 등은 질병에 대한 저항력을 높여 주고 위에서 흡수되어 산성체질을 개선하는 효과가 있다.Vinegar is widely used not only for food preservation but also as food fragrances or remedies. In general, vinegar not only improves the taste of the food itself, it also alleviates the salty taste and neutralizes the fat. Vinegar is also known as a good raw material for the treatment of various adult diseases, which cleanses the blood and is effective in restoring fatigue. In addition, the organic acids and amino acids contained in vinegar, such as increasing resistance to disease and absorbed from the above has the effect of improving the acidic constitution.
식초는 초산 이외의 각종 휘발성 및 비휘발성 유기산류, 당류, 아미노산류, 에스테르류를 함유하고 있어 식욕을 자극하는 방향과 맛을 가지며 생체 조직 내에서 쉽게 분해되어 다른 열량원보다 빠르게 칼로리를 발생하는 스테미너 식품으로 알려져 있다. 천연식초는 동맥경화, 고혈압 등의 성인병 예방효과, 식중독균의 살균효과, 콜레스테롤 저하효과, 체지방 감소 및 피로회복 효과 등에 관한 연구가 보고되면서 기능성 식품으로 인정되고 있고 다양한 용도로의 개발이 진행되고 있다. 또한, 천연식초는 우리 몸에 파로틴의 분비를 촉진하여 세포의 노화를 막고 뼈를 강하게 하고, 체내의 칼슘 흡착력을 높여 골의 질량을 늘리는 기능도 알려져 있다.Vinegar contains various volatile and nonvolatile organic acids, saccharides, amino acids and esters other than acetic acid. It has a direction and taste to stimulate the appetite and is easily decomposed in the living tissue to generate calories faster than other calorie sources. It is known as food. Natural vinegar has been recognized as a functional food and has been developed for a variety of uses as a result of studies on prevention of adult diseases such as arteriosclerosis and hypertension, sterilization effect of food poisoning bacteria, cholesterol lowering effect, reduction of body fat and fatigue recovery. In addition, the natural vinegar to promote the secretion of parotin in our body to prevent aging cells, strengthening the bones, increasing the body's calcium absorption capacity is known to increase the mass of the bone.
한편, 비만은 체내에 지방이 필요 이상으로 과도하게 쌓인 경우를 말하며, 국민 건강통계에 따르면 비만 유병률은 1998년 26.0%에서 2011년 31.4%로, 증가 추이를 보인다. 특히 비만은 다양한 성인병의 합병증과 관련이 있는 것으로 밝혀지고 있다. 예를 들어, 비만환자는 정상 체중인 사람에 비하여 간경변증 질환의 경우 2배, 뇌혈관질환의 경우 1.6배 및 관상동맥질환의 경우 1.8배 정도 사망률이 높은 것으로 보고되어 있다. On the other hand, obesity refers to a case where the body is excessively overgrown, and according to the national health statistics, the prevalence of obesity is increasing from 26.0% in 1998 to 31.4% in 2011. Obesity has been found to be associated with complications of various adult diseases. For example, obesity patients have been reported to have a higher mortality rate compared to those who have normal weight, twice as much in the case of cirrhosis, 1.6 times in the case of cerebrovascular disease and 1.8 times in the case of coronary artery disease.
현재, 비만에 대한 치료방법으로 식이요법, 운동요법 및 약물요법 등이 시도되고 있으며, 이 중 약물요법으로 사용되는 비만치료제는 식욕의 조절, 지방의 소화흡수 방해, 에너지 소비의 증가 또는 지질대사의 조절 등을 타겟으로 개발되었으나, 다양한 부작용이 존재한다. 제니칼(로슈)은 췌장 및 소화계에서 분리되는 리파아제 억제를 유도하여 지방흡수를 억제하지만, 겨우 2~3%의 낮은 체중감량 효과를 보이며, 잦은 설사, 지방변 등의 부작용을 동반한다. 또한, 리덕틸(애보트)은 세로토닌과 노르아드레날린의 재흡수 억제를 통해 식욕을 억제시킴으로써, 5~10%의 체중감량효과가 있으나, 뇌졸증과 심근경색 등 심혈관계 질환의 부작용이 있어, 2010년 유럽 의약품 안전청(EMA)과 미국 식품의약품안전청(FDA)이 처방과 사용중지 및 자발적 회수 권고조치를 내려 시장에서 퇴출되었으며, 국내에서는 2010년 10월경 식품의약품안전청에 의해 판매가 중단되었다. 이외에도 항비만 약제로 개발된 제품 중에서 심각한 부작용으로 인해 판매가 금지된 것들이 상당수에 이른다. 예로 아미노필린은 탁월한 체지방 분해효과에도 불구하고 정신신경계, 순환기계, 소화기계에 걸쳐 폭넓은 부작용이 보고된 바 있고, 펜프루라민, 덱스펜플루라민, 토피라메이 또는 에피드린 등도 비만치료에 부적합한 약물로 판정되어 판매가 금지되었다. 이와 같이 합성의약품의 부작용과 만성질환의 극복에 서양의학이 한계를 보임에 따라 항비만 효과를 가진 천연물 식의약품에 대한 가치가 새롭게 부각되고 있다. Currently, obesity treatment methods such as dieting, exercise therapy, and drug therapy are being tried. Among them, the therapeutic agent for obesity used as a drug therapy is an agent for controlling appetite, interfering with digestion and absorption of fat, Control, etc., but there are various side effects. Xenical (Roche) inhibits fat absorption by inducing lipase inhibition in the pancreas and digestive system, but has a low weight loss effect of only 2 to 3% and is accompanied by frequent side effects such as diarrhea and fatty liver. In addition, reductil (Abbott) inhibits appetite by inhibiting the reuptake of serotonin and noradrenaline, thereby reducing body weight by 5 ~ 10%. However, there are side effects of cardiovascular diseases such as stroke and myocardial infarction, The EMA and the US Food and Drug Administration (FDA) withdrew from the market with prescription, suspension and voluntary recall recommendations, and were discontinued by the Food and Drug Administration in October 2010 in Korea. In addition, many of the products developed as anti-obesity drugs are prohibited from selling due to serious side effects. For example, aminophylline has been reported to have widespread adverse effects on the mental nervous system, circulatory system, and digestive system, despite its excellent body fat degradation, and penfluramine, dexfenfluramine, topiramime, or ephedrine, Sales were banned. As such, the value of natural medicines with anti-obesity effects is newly emerging as Western medicine is limited in the side effects of synthetic drugs and overcoming of chronic diseases.
또한, 염증(inflammation)은 물리적인 상처나 미생물에 감염되었을 때 일어나는 정상적인 생체의 방어기전(defense mechanism)의 일종이며 이 염증작용을 통하여 발병요인(pathogen)을 중화시키거나 제거하고, 손상된 조직을 복구시켜 정상적인 구조와 기능을 하게 한다. 염증을 동반하는 대부분의 질환은 조직의 손상, 통증 및 가려움증과 같은 삶의 질을 떨어뜨리는 결과를 초래하고, 만성적인 염증상태는 관절염, 천식, 뇌와 척수의 다발성 경화증, 염증성 장 질환 및 동맥 경화증을 일으킨다. 대식세포는 선천면역을 담당하는 주요 세포로, 사이토카인 및 박테리아 지질다당류 내독소(lipopolysaccharide, LPS) 같은 수많은 인자에 의해 활성화되고, 활성화된 대식세포는 산화질소(nitric oxide, NO) 및 프로스타글란딘E2(prostaglandin E2, PGE2) 같은 염증 인자는 물론 TNF-α(tumor necrosis factor-α), IL-6(interleukin-6), IL-1(interleukin-1) 같은 전염증성 사이토카인을 생산한다. NO는 자유 라디칼(free radical)의 일종으로 산화질소 합성효소(nitric oxide synthase, NOS)에 의해 합성되며, eNOS(endothelial NOS), nNOS(neuronal NOS) 및 iNOS(inducible NOS)의 3개의 동형 단백질(isoform)이 존재한다. IL-1, TNF-α, 인터페론-감마(interferon-gamma) 같은 전염증성 사이토카인들은 iNOS 발현을 유발하고 NO 생산을 일으킬 수 있다. 뇌암, 유방암, 폐암, 전립선암, 췌장암 및 흑색종 같은 많은 악성암들이 iNOS 발현과 연관되어 있고, 과도한 NO의 생산은 상피세포암, 돌연변이 및 DNA 구조 손상을 일으킬 수 있다. 일반적으로 COX 단백질은 COX-1과 COX-2 두가지 동형 단백질(isoforms)로 존재하고, 염증 반응동안 COX-2에 의해 PGE2가 생성된다. 또한, COX-2의 발현은 세포 손상, 고통, 부종 및 열, 신생혈관 형성 및 전이 같은 종양생성과 깊은 관련이 있다. NF-κB는 염증 반응에서 중요한 역할을 하는 전사인자이며, LPS와 반응하여 대식세포는 TLR4(Toll-like receptor 4)에 의한 Myd88(myeloid differentiation factor 88)을 활성화한다. 활성화된 Myd88은 TAK1(transforming growth factor--activated protein kinase 1)을 활성화하고, TAK1은 IκB(inhibitor of NF-κB)의 분해(degradation)를 통해서 NF-κB를 활성화 시킨다. 이를 통해 NF-κB는 최종적으로 염증 매개 인자들을 분비하여 염증을 일으킨다. In addition, inflammation is a normal defense mechanism of a living body that occurs when a physical injury or microorganism is infected. This inflammation neutralizes or eliminates the pathogen, To allow normal structure and function. Most of the diseases with inflammation result in deterioration of quality of life such as tissue damage, pain and itching, and chronic inflammatory conditions include arthritis, asthma, multiple sclerosis of brain and spinal cord, inflammatory bowel disease and arteriosclerosis ≪ / RTI > Macrophages are the main cells responsible for innate immunity. They are activated by a number of factors such as cytokines and bacterial lipopolysaccharide (LPS), and activated macrophages are nitric oxide (NO) and prostaglandin E 2 (prostaglandin E 2 , PGE 2 ) as well as proinflammatory cytokines such as TNF-α, IL-6 (interleukin-6) and IL-1 (interleukin-1). NO is a free radical that is synthesized by nitric oxide synthase (NOS) and is composed of three isoforms of endothelial NOS, nNOS, and iNOS (inducible NOS) isoform. Proinflammatory cytokines such as IL-1, TNF-a, and interferon-gamma can induce iNOS expression and cause NO production. Many malignant cancers, such as brain cancer, breast cancer, lung cancer, prostate cancer, pancreatic cancer, and melanoma, are associated with iNOS expression, and excessive NO production can cause epithelial cancer, mutations, and damage to DNA structures. Generally, COX proteins are present as isoforms of both COX-1 and COX-2, and PGE 2 is produced by COX-2 during the inflammatory reaction. In addition, COX-2 expression is strongly associated with tumorigenesis such as cell damage, pain, edema and heat, neovascularization and metastasis. NF-κB is a transcription factor that plays an important role in the inflammatory response. In response to LPS, macrophages activate Myd88 (myeloid differentiation factor 88) by TLR4 (Toll-like receptor 4). Activated Myd88 activates transforming growth factor-activated protein kinase 1 (TAK1) and TAK1 activates NF-κB through degradation of IκB (inhibitor of NF-κB). Thus, NF-κB eventually releases inflammatory mediators and causes inflammation.
더욱이, 사람의 피부색을 결정하는 데는 여러 요인들이 관여하는데, 그 중에서도 멜라닌 색소를 만드는 멜라노사이트(melanocyte)의 활동성, 혈관의 분포, 피부의 두께 및 카로티노이드, 빌리루빈 등의 인체 내외의 색소 관련 요인들이 중요하다. 특히, 가장 중요한 요인은 인체 내의 멜라노사이트에서 타이로시나제 등의 여러 효소가 작용하여 생성되는 멜라닌이라는 색소이다. 피부의 색소침착은 자외선이나 염증 등의 자극에 의해 야기되며 또 유전적 요인이나 호르몬, 식품 등과 화학물질 등의 인자에 의해서도 발생된다고 알려져 있다. 특히 기미, 주근깨, 색소침착 등과 같은 피부색소 이상침착 증상에 프로스타글란딘(prostaglandins), 히스타민(histamine), 알파-MSH(alpha-MSH), NO(Nitric oxide) 같은 염증 관련 인자가 관여되어 멜라노사이트(melanocyte) 내에서 멜라닌 생성을 활성화시키는 것은 잘 알려져 있다. 또한, 조직의 손상과 재생과정에서도 면역학적 매개체에 의해 과색소 침착이 수반된다는 보고도 있다. Furthermore, various factors are involved in determining the skin color of a person. Among them, the activity of melanocyte which forms a melanin pigment, distribution of blood vessels, thickness of skin, carotenoid, bilirubin, Do. In particular, the most important factor is melanin, which is produced by the action of various enzymes such as tyrosinase in melanocytes in the human body. Skin pigmentation is caused by stimuli such as ultraviolet rays or inflammation, and it is also known to be caused by factors such as genetic factors, hormones, foods, and chemicals. In particular, inflammation related factors such as prostaglandins, histamine, alpha-MSH, and NO (nitric oxide) have been implicated in skin pigmentation abnormalities such as spots, freckles and pigmentation, and melanocytes ) Is known to activate melanin production. It is also reported that hyperpigmentation is accompanied by immunological mediators in the process of tissue damage and regeneration.
멜라닌 색소 합성을 구체적으로 살펴보면 멜라닌 세포(melanocytes)가 여러 요인에 의해 자극을 받으면 티로시나아제(tyrosinase)가 멜라노좀(melanosome)에서 멜라닌을 생성한다. 즉, 멜라닌 세포 내 티로신은 티로시나아제의 작용으로 도파(dopa)로 변하고, 이어 도파옥시다제(dopaoxidase)의 작용으로 도파퀴논(dopaquinone)으로 변한 후, 티로시나아제 관련 단백질-1(tyrosinase-related protein-1, 이하 TRP-1이라고 명기)과 티로시나아제 관련 단백질-2(tyrosinase-related protein-2, 이하 TRP-2이라고 명기)의 작용에 의하여 멜라닌을 생성한다. 이러한 일련의 반응에서 티로시나아제는 멜라닌 색소 형성 과정의 속도-제한 반응을 활성화시키므로, 멜라닌 형성은 티로시나아제의 활성 및 발현에 의하여 1차적으로 제어된다. 또한, DOPA 크롬 상호변이효소로 알려진 TRP-2는 DOPA 크롬의 5,6-디하이드록시인돌-2-카르복실산(DHICA)로의 반응을 활성화시키고, TRP-1는 DHICA를 카르복실 인돌-퀴논으로 산화시킨다. 결과적으로 TRP-1 및 TRP-2는 불용성 색소인 멜라닌 형성의 최종단계인 중합반응에 관여한다. 이들 티로시나아제(tyrosinase), TRP-1(tyrosinase-related protein-1), TRP-2(tyrosinase-related protein-2)는 염증 매개물질에 의해 활성이 증가되어 멜라닌의 합성이 증가된다는 보고가 있다.When melanocytes are stimulated by various factors, tyrosinase produces melanin in the melanosome. As a result, melanocytes are melanosomes. That is, tyrosine in melanocytes is transformed into dopa by the action of tyrosinase and then transformed into dopaquinone by the action of dopaoxidase, and then tyrosinase-related related protein-2 (hereinafter referred to as TRP-2) and tyrosinase-related protein-2 (hereinafter referred to as TRP-2) to produce melanin. In this series of reactions, tyrosinase activates the rate-limiting reaction of the melanin pigmentation process, so that melanogenesis is primarily controlled by the activity and expression of tyrosinase. TRP-2, also known as the DOPA chromium mutant enzyme, activates the reaction of DOPA chromium with 5,6-dihydroxyindole-2-carboxylic acid (DHICA), TRP-1 activates DHICA with carboxylindole- . As a result, TRP-1 and TRP-2 are involved in the polymerization reaction, which is the final stage of melanin formation, an insoluble pigment. It has been reported that tyrosinase, tyrosinase-related protein-1 (TRP-1) and tyrosinase-related protein-2 (TRP-2) are activated by inflammatory mediators to increase the synthesis of melanin .
현재 개발된 미백제로는 코지산, 알부틴, 글루타치온, 비타민 C 등이 있지만 소비자들이 만족할 만한 미백효과를 갖지 못하고 있으며, 피부 안전성 때문에 그 사용량이 제한적이다. 따라서 멜라닌 합성단계별로 다양한 시도가 이루어져 왔다.Currently developed whitening agents include kojic acid, arbutin, glutathione and vitamin C, but consumers do not have a satisfactory whitening effect and their use is limited due to skin safety. Thus, various attempts have been made to synthesize melanin.
한편, 단풍취(Mapleleaf ainsliaea)는 국화과에 속하는 다년생초로, 잎이 줄기에 4~7장 모여나고 단풍나무잎처럼 7~11갈래로 갈라졌는데 그 생김새가 단풍나무와 비슷한 취나물이라고 해서 단풍취라고 부른다. 이러한 단풍취의 어린잎은 나물로 먹을 수 있고, 뿌리를 제외한 풀 전체는 약용으로 쓰이며, 비타민, 무기질, 칼륨이 풍부할 뿐 아니라 숙취해소, 동맥경화, 고혈압, 류마티스 관절염, 장염에 효능이 있다고 알려져 있으나, 항비만, 항염증 및 피부 미백 효과에 대한 연구는 미비한 실정이며, 상기 단풍취를 이용하여 식초를 제조하는 기술은 개발되지 않았다. On the other hand, Maplea ainsliaea belongs to Asteraceae, a perennial herbaceous herb, 4-7 leafs gathered on the stem and 7-11 split like maple leaves. The young leaves of this sweetweed can be eaten as herbs, and the whole paste, except for roots, is used for medicinal purposes. It is rich in vitamins, minerals and potassium, and is known to be effective in relieving hangover, arteriosclerosis, hypertension, rheumatoid arthritis and enteritis , Anti-obesity, antiinflammation and skin whitening effect. However, no technique for producing vinegar using the above-mentioned sweet-and-dried breeze has been developed.
한편, 한국공개특허 제10-2010-0133720호에는 고추 식초의 제조방법이 개시되어 있으나, 본 발명의 단풍취를 이용한 항비만, 항염증 및 피부 미백 효능이 증진된 식초 및 그 제조방법에 대해 개시된 바 없다. Korean Patent Laid-Open No. 10-2010-0133720 discloses a process for producing red pepper vinegar. However, the present invention provides a vinegar having improved anti-obesity, anti-inflammatory and skin whitening effect using the present invention, none.
본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 본 발명자는 단풍취를 이용한 식초 및 그 제조방법을 제공하고, 식초 제조로 인해 동맥경화, 고혈압 등의 성인병 예방과, 식중독균의 살균, 콜레스테롤 저하, 체지방 감소 및 피로회복을 향상시킬 뿐 아니라 항비만, 항염증 및 피부 미백 개선 효과가 증진되는 것을 확인함으로써, 본 발명을 완성하였다. SUMMARY OF THE INVENTION The present invention has been made in view of the above-mentioned needs, and it is an object of the present invention to provide a vinegar and a method for producing vinegar by using a single puff breeze to prevent veterinary diseases such as arteriosclerosis and hypertension, sterilization of food poisoning bacteria, Reduction in skin fatigue and improvement in fatigue recovery as well as improvement in anti-obesity, anti-inflammatory and skin whitening improvement effects.
상기 과제를 해결하기 위해, 본 발명은In order to solve the above problems,
(a) 단풍취를 세척하는 단계; (a) washing the deodorizer;
(b) 상기 단계 (a)에서 세척한 단풍취에 용매를 첨가하여 추출물을 제조하는 단계;(b) preparing an extract by adding a solvent to the deodorized leaves collected in step (a);
(c) 상기 단계 (b)에서 제조된 단풍취 추출물에 초산균을 접종하여 초산 발효물을 제조하는 단계; 및 (c) preparing acetic acid fermented product by inoculating acetic acid to the extract of monoptera produced in step (b); And
(d) 상기 단계 (c)에서 제조된 초산 발효물을 여과하고 숙성시켜 식초를 제조하는 단계;를 포함하는 것을 특징으로 하는 항비만, 항염증 및 피부 미백 효능이 증진된 단풍취 식초의 제조방법을 제공한다.and (d) filtering and aging the fermented acetic acid produced in step (c) to produce a vinegar. The method for producing vinegar having improved anti-obesity, anti-inflammation and skin whitening effect, to provide.
또한, 본 발명은 상기 제조방법으로 제조된 항비만, 항염증 및 피부 미백 효능이 증진된 단풍취 식초를 제공한다.In addition, the present invention provides a dried pine flower vinegar having improved anti-obesity, anti-inflammatory and skin whitening efficacy produced by the above-described method.
또한, 본 발명은 상기 단풍취 식초를 유효성분으로 함유하는 비만의 예방 또는 개선용 건강기능식품 조성물을 제공한다. In addition, the present invention provides a health functional food composition for preventing or ameliorating obesity, which comprises the above-mentioned P. vestibule as an effective ingredient.
또한, 본 발명은 상기 단풍취 식초를 유효성분으로 함유하는 염증의 예방 또는 개선용 건강기능식품 조성물을 제공한다. Further, the present invention provides a health functional food composition for preventing or ameliorating inflammation, which contains the above-mentioned dried vinegar as an active ingredient.
또한, 본 발명은 상기 단풍취 식초를 유효성분으로 함유하는 멜라닌 색소 과다 침착 질환의 예방 또는 개선용 건강기능식품 조성물을 제공한다.The present invention also provides a health functional food composition for preventing or ameliorating a melanin pigment hyperpigmentation disease, which comprises the above-mentioned monocotyledonous vinegar as an active ingredient.
본 발명은 단풍취를 이용한 항비만, 항염증 및 피부 미백 효능이 증진된 식초 및 그 제조방법에 관한 것으로, 본 발명의 제조방법에 의해 제조된 식초는 통상적으로 처리되는 알콜 발효를 거치지 않고 초산 발효과정만을 통해 단풍취의 유효성분을 효과적으로 이용할 수 있을 뿐 아니라 생산 공정 시간을 단축하여 가격 경쟁력도 확보할 수 있다.The present invention relates to a vinegar having improved anti-obesity, anti-inflammatory and skin whitening efficacy using a single-pest, and a process for producing the same, and the vinegar produced by the process of the present invention can be produced by a fermentation process It is possible not only to effectively utilize the effective ingredient of the ventilator but also to shorten the production process time and to secure price competitiveness.
또한, 식초 고유의 기능인 동맥경화, 고혈압 등의 성인병 예방과, 식중독균의 살균, 콜레스테롤 저하, 체지방 감소 및 피로회복뿐 아니라 단풍취를 초산 발효함으로써 우수한 항비만, 항염증 및 피부 미백 효과를 나타낸다.In addition, it exhibits excellent anti-obesity, anti-inflammation and skin whitening effect by prevention of adult diseases such as arteriosclerosis and hypertension which are inherent functions of vinegar, sterilization of food poisoning bacteria, reduction of cholesterol, reduction of body fat and fatigue,
도 1은 본 발명의 제조방법에 따른 단풍취 추출물 또는 초산 발효물의 지방생성 억제효과(a), 멜라닌 생합성 저해 효과(b) 및 NO 생성 억제 효과(c)를 확인한 결과이다. MDI(IBMX(3-isobutyl-1-methylxanthine), 덱사메타손(dexamethasone), 인슐린(insulin)의 혼합물)는 분화 유도 물질로, 지방전구세포인 3T3-L1의 분화를 유도하기 위해 사용하였다. α-MSH는 멜라닌 생합성을 촉진하기 위해 처리하였고, LPS는 NO의 생성을 촉진하기 위해 처리하였다. 알부틴(arbutin)은 멜라닌 생합성 저해효과를 확인하기 위한 양성대조군이고, 물 추출물은 단풍취 물 추출물이고, 물 초산 발효는 단풍취 물 추출물을 초산 발효한 식초이고, 에탄올 추출물은 단풍취 에탄올 추출물이며, 에탄올 초산 발효는 단풍취 에탄올 추출물을 초산 발효한 식초이다. Fig. 1 shows the results of confirming the effect (a), melanin biosynthesis inhibition effect (b) and NO production inhibitory effect (c) of the monoptera extract or acetic acid fermented product according to the production method of the present invention. MDI (a mixture of 3-isobutyl-1-methylxanthine, dexamethasone, and insulin) was used as a differentiation inducing substance to induce the differentiation of 3T3-L1 as a lipogenic precursor cell. α-MSH was treated to promote melanin biosynthesis, and LPS was treated to promote the production of NO. Arbutin is a positive control for confirming inhibition of melanin biosynthesis. Water extract is a single-bladed water extract. Water acetic acid fermentation is an acetic acid fermented vinegar of water extract of a single blind, Is an acetic acid-fermented vinegar with ethanol extract of sweet breeze.
본 발명은 The present invention
(a) 단풍취를 세척하는 단계; (a) washing the deodorizer;
(b) 상기 단계 (a)에서 세척한 단풍취에 용매를 첨가하여 추출물을 제조하는 단계;(b) preparing an extract by adding a solvent to the deodorized leaves collected in step (a);
(c) 상기 단계 (b)에서 제조된 단풍취 추출물에 초산균을 접종하여 초산 발효물을 제조하는 단계; 및 (c) preparing acetic acid fermented product by inoculating acetic acid to the extract of monoptera produced in step (b); And
(d) 상기 단계 (c)에서 제조된 초산 발효물을 여과하고 숙성시켜 식초를 제조하는 단계;를 포함하는 것을 특징으로 하는 항비만, 항염증 및 피부 미백 효능이 증진된 단풍취 식초의 제조방법을 제공한다. and (d) filtering and aging the fermented acetic acid produced in step (c) to produce a vinegar. The method for producing vinegar having improved anti-obesity, anti-inflammation and skin whitening effect, to provide.
상기 단계 (b)에서 첨가한 용매는 C1 내지 C4의 저급 알코올, 물 또는 이들의 혼합물이며, 바람직하게는 에탄올이지만 이에 한정하지 않는다. The solvent added in step (b) is a C 1 to C 4 lower alcohol, water or a mixture thereof, preferably ethanol, but is not limited thereto.
상기 단계 (c)에서 접종된 초산균은 바람직하게는 아세토박터 속(Acetobacter sp.)이지만 이에 제한되지 않는다.The inoculated acetic acid bacteria in step (c) is preferably Acetobacter sp. But is not limited thereto.
상기 단풍취 식초의 제조방법으로 제조된 단풍취 식초는 지방생성, 멜라닌 합성 및 NO 생성 저해능이 단풍취 추출물에 비해 더욱 증진되며, 항비만, 항염증 및 피부 미백 효능을 나타내지만 이에 제한되지 않는다.The edible vinegar produced by the method for producing the pine-blade vinegar has a higher inhibitory effect on lipogenesis, melanin synthesis, and NO production than that of the P. aeruginosa extract, and exhibits anti-obesity, anti-inflammatory and skin whitening efficacy.
또한, 본 발명은 상기 방법으로 제조된 항비만, 항염증 및 피부 미백 효능이 증진된 단풍취 식초를 제공한다. In addition, the present invention provides a monocotyledonous vinegar having an anti-obesity, anti-inflammatory and skin whitening effect produced by the above method.
또한, 본 발명은 상기 단풍취 식초를 유효성분으로 함유하는 비만의 예방 또는 개선용 건강기능식품 조성물을 제공한다. In addition, the present invention provides a health functional food composition for preventing or ameliorating obesity, which comprises the above-mentioned P. vestibule as an effective ingredient.
또한, 본 발명은 상기 단풍취 식초를 유효성분으로 함유하는 염증의 예방 또는 개선용 건강기능식품 조성물을 제공한다. Further, the present invention provides a health functional food composition for preventing or ameliorating inflammation, which contains the above-mentioned dried vinegar as an active ingredient.
또한, 본 발명은 상기 단풍취 식초를 유효성분으로 함유하는 멜라닌 색소 과다 침착 질환의 예방 또는 개선용 건강기능식품 조성물을 제공한다. The present invention also provides a health functional food composition for preventing or ameliorating a melanin pigment hyperpigmentation disease, which comprises the above-mentioned monocotyledonous vinegar as an active ingredient.
본 명세서에서 사용되는 용어 "멜라닌 색소 과다 침착(hyperpigmentation)"은 피부 또는 손발톱의 특정 부위에서 멜라닌의 과도한 증가에 의해 다른 부위에 비해 검게 또는 어둡게 되는 것을 의미한다. 상기 멜라닌 색소 과다 침착 질환은 주근깨, 노인성 반점, 간반, 기미, 갈색 또는 흑점, 일광 색소반, 푸른흑피증(cyanic melasma), 약물 사용 후의 과다 색소 침착, 찰상, 화상 또는 피부염으로 인한 염증 후 과다 색소 침착 또는 임신성 갈색반(gravidic chloasma) 등을 포함하나 이에 한정되지 않는다.As used herein, the term " melanin pigment hyperpigmentation "means darkening or darkening compared to other areas due to excessive increase of melanin in specific areas of the skin or nail. The melanin pigment hyperpigmentation disorder is a hyperpigmentation disorder caused by inflammation caused by freckles, senile spots, liver, spots, brown or black spots, daylight pigmentation, cyanic melasma, hyperpigmentation after drug use, scratches, burns or dermatitis Including but not limited to implantation, deposition or gravidic chloasma, and the like.
본 발명의 건강기능식품 조성물을 식품첨가물로 사용하는 경우, 상기 건강기능식품 조성물을 그대로 첨가하거나 다른 식품 또는 식품성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 양은 그의 사용 목적(예방 또는 개선)에 따라 적절하게 사용될 수 있다. 일반적으로, 식품 또는 음료의 제조시 본 발명의 건강기능식품 조성물은 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가된다. 그러나 건강을 목적으로 하는 장기간의 섭취인 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로 사용될 수 있다.When the health functional food composition of the present invention is used as a food additive, the health functional food composition may be added as it is, or may be used together with other food or food ingredients, and suitably used according to a conventional method. The amount of the active ingredient can be suitably used depending on its use purpose (prevention or improvement). Generally, the health functional food composition of the present invention is added in an amount of not more than 15 parts by weight, preferably not more than 10 parts by weight based on the raw material, when the food or beverage is produced. However, in the case of long-term consumption intended for health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount of more than the above range.
상기 건강기능식품의 종류에 특별한 제한은 없다. 상기 건강기능식품 조성물을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차 드링크제, 알코올음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of the health functional food. Examples of the foods to which the health functional food composition can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen and other noodles, gums, ice cream, soups, Alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.
또한, 본 발명의 건강기능식품 조성물은 식품, 특히 기능성 식품으로 제조될 수 있다. 본 발명의 기능성 식품은 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소 및 조미제를 포함한다. 예컨대, 드링크제로 제조되는 경우에는 유효성분 이외에 천연 탄수화물 또는 향미제를 추가 성분으로서 포함시킬 수 있다. 상기 천연 탄수화물은 모노사카라이드(예컨대, 글루코오스, 프럭토오스 등), 디사카라이드(예컨대, 말토스, 수크로오스 등), 올리고당, 폴리사카라이드(예컨대, 덱스트린, 시클로덱스트린 등) 또는 당알코올(예컨대, 자일리톨, 소르비톨, 에리쓰리톨 등)인 것이 바람직하다. 상기 향미제는 천연 향미제(예컨대, 타우마틴, 스테비아 추출물 등)와 합성 향미제(예컨대, 사카린, 아스파르탐 등)를 이용할 수 있다.In addition, the health functional food composition of the present invention can be produced as a food, particularly a functional food. The functional food of the present invention includes components that are ordinarily added in food production, and includes, for example, proteins, carbohydrates, fats, nutrients, and seasonings. For example, in the case of a drink, a natural carbohydrate or a flavoring agent may be included as an additional ingredient in addition to the active ingredient. The natural carbohydrate may be selected from the group consisting of monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose etc.), oligosaccharides, polysaccharides (e.g., dextrin, cyclodextrin, , Xylitol, sorbitol, erythritol, etc.). The flavoring agent may be a natural flavoring agent (e.g., tau Martin, stevia extract, etc.) and a synthetic flavoring agent (e.g., saccharin, aspartame, etc.).
상기 건강기능식품 조성물 이외에 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 더 함유할 수 있다. 이러한 상기 첨가되는 성분의 비율은 크게 중요하진 않지만 본 발명의 건강기능식품 조성물 100 중량부에 대하여, 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above-mentioned health functional food composition, it is possible to use various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, A carbonating agent used in beverages, and the like. Although the ratio of the above-mentioned ingredients is not critical, it is generally selected in the range of 0.01 to 0.1 part by weight based on 100 parts by weight of the health functional food composition of the present invention.
이하, 본 발명의 제조예 및 실시예를 들어 상세히 설명한다. 단, 하기 제조예 및 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 제조예 및 실시예에 한정되는 것은 아니다.Hereinafter, production examples and examples of the present invention will be described in detail. However, the following Preparation Examples and Examples are illustrative of the present invention, and the content of the present invention is not limited to the following Production Examples and Examples.
제조예Manufacturing example 1. One. 단풍취A single blow 추출물 및 식초의 제조 Preparation of extracts and vinegar
1) 단풍취 물 추출물의 제조1) Preparation of water extract
건조하여 분쇄한 단풍취 10g에 증류수를 100㎖ 넣고, 180rpm으로 12시간 동안 가열교반하여 추출한 후, 12,000rpm에서 15분 동안 원심 분리한 뒤 여과하여 시료로 사용하였다.100 ml of distilled water was added to 10 g of dried and pulverized cutworms, and the mixture was heated and stirred at 180 rpm for 12 hours. The mixture was centrifuged at 12,000 rpm for 15 minutes and filtered to use as a sample.
2) 단풍취 물 초산 발효 식초의 제조2) Manufacture of acetic acid fermented vinegar with single-blasted water
상기 단풍취 물 추출물에 10%의 설탕을 첨가한 후, 사카로마이세스 세레비지애(Saccharomyces cerevisiae) 균주를 접종하여 30℃에서 96시간 동안 발효한 알코올 발효액에 초산 균주인 아세토박터 속(Acetobacter sp.)을 접종하여 30℃에서 180rpm으로 72시간 배양하였다. 배양된 초산발효액은 12,000rpm에서 15분 동안 원심 분리한 뒤 여과하여 시료로 사용하였다. The danpungchwi followed by the addition of sugar, 10% of the water extract, saccharide as MY process three Levy jiae (Saccharomyces cerevisiae) the speed from 30 ℃ one of acetonitrile bakteo acetate strain in alcohol fermentation broth fermentation for 96 hours was inoculated strain (Acetobacter sp. ) Was inoculated and cultured at 30 DEG C and 180 rpm for 72 hours. The cultured acetic acid fermentation broth was centrifuged at 12,000 rpm for 15 minutes and filtered to use as a sample.
3) 단풍취 에탄올 추출물의 제조3) Production of ethanol extract
건조하여 분쇄한 단풍취 10g에 60%(v/v) 에탄올을 100㎖ 넣고, 상온에서 180rpm으로 2시간 동안 교반하여 추출한 후, 12,000rpm에서 15분 동안 원심 분리한 뒤 여과하여 시료로 사용하였다. 100 g of 60% (v / v) ethanol was added to 10 g of the dried and pulverized broccoli, and the mixture was stirred at 180 rpm for 2 hours at room temperature. The mixture was centrifuged at 12,000 rpm for 15 minutes and filtered.
4) 단풍취 에탄올 초산 발효 식초의 제조4) Manufacture of acetic acid fermented vinegar with ethanol
상기 단풍취 에탄올 추출물을 증류수로 희석하여 에탄올 함량을 6%(v/v)로 조정한 뒤 초산 균주인 아세토박터 속(Acetobacter sp.)을 접종하여 30℃에서 180rpm으로 72시간 배양하여 초산발효하였다. 배양된 초산발효액은 12,000rpm에서 15분 동안 원심 분리한 뒤 여과하여 시료로 사용하였다.The ethanol extract was diluted with distilled water to adjust the ethanol content to 6% (v / v). Then, the acetic acid bacteria Acetobacter sp.) and incubated at 30 캜 for 180 hours at 180 rpm for acetic acid fermentation. The cultured acetic acid fermentation broth was centrifuged at 12,000 rpm for 15 minutes and filtered to use as a sample.
실시예Example 1. One. 단풍취A single blow 추출물 및 식초의 지방생성 억제효과 확인 Identification of inhibitory effect of extracts and vinegar on lipogenesis
제조예 1의 단풍취 물 추출물, 물 초산 발효 식초, 에탄올 추출물, 에탄올 초산 발효 식초의 지방생성 억제효과를 지방전구세포인 3T3-L1을 이용하여 확인하였다. 3T3-L1의 지방생성 정도는 Lipid(Oil Red-O) staining kit(sigma, USA)를 이용한 염색을 통하여 측정하였다. 제조예 1의 농도별(25 및 50㎍/㎖) 단풍취 추출물 또는 식초와 분화유도물질(MDI)을 함께 처리하여 분화시키고, 그 후 10% 포르말린이 포함된 인산완충액(phosphatate buffer saline, PBS)을 처리하여 실온에서 고정한 후, 이를 제거하고, 60% 이소프로판올(isopropanol)로 씻어준 뒤 건조하였다. 그 후, Oil Red-O를 넣고, 45분 동안 염색한 후 증류수로 4번 세척하고, 증류수를 완벽히 제거하였다. 그 후, 세포에 100% 이소프로판올을 넣고 180rpm에서 10분 동안 지방에 염색된 Oil Red-O를 추출하고, 그 값을 520㎚ 흡광도를 이용하여 측정하였다. The liposome-inhibiting effect of the water extract of monoculture, acetic acid fermented vinegar, ethanol extract, and ethanolic acetic acid fermented vinegar of Preparation Example 1 was confirmed by using 3T3-L1 as a lipid precursor cell. The degree of fat production of 3T3-L1 was measured by staining with a lipid (Oil Red-O) staining kit (Sigma, USA). (25 and 50 μg / ml) of the culture of Preparation Example 1 or vinegar and differentiation inducing substance (MDI) were separately treated, and then 10% formalin-containing phosphate buffer (PBS) After fixed at room temperature, it was removed, washed with 60% isopropanol and dried. After that, Oil Red-O was added, stained for 45 minutes, washed 4 times with distilled water, and the distilled water was completely removed. After that, 100% isopropanol was added to the cells, and Oil Red-O stained with fat was extracted for 10 minutes at 180 rpm, and the value was measured using absorbance at 520 nm.
그 결과, 도 1(a)에 나타난 바와 같이 단풍취 에탄올 추출물 50㎍/㎖ 처리구와 단풍취 에탄올 초산 발효 식초 25 및 50㎍/㎖ 처리구에서 지방생성 억제효과를 확인하였으며, 단풍취 에탄올 추출물에 비해 에탄올 추출물의 초산 발효 식초의 지방생성 억제효과가 더욱 증진되는 것을 확인하였다. As a result, as shown in Fig. 1 (a), the effect of inhibiting adipocyte formation was confirmed in the treatment of 50 ㎍ / ㎖ ethanol extract of cutworms and 25 and 50 ㎍ / ㎖ of ethanolic acetic acid fermented vinegar. It was confirmed that the effect of inhibiting the lipogenesis of the acetic acid fermented vinegar was further enhanced.
실시예Example 2. 2. 단풍취A single blow 추출물 및 식초의 멜라닌( Extracts and melanin in vinegar ( melaninmelanin ) 생합성 저해효과 확인) Confirmation of biosynthesis inhibition effect
제조예 1의 단풍취 물 추출물, 물 초산 발효 식초, 에탄올 추출물, 에탄올 초산 발효 식초의 멜라닌 생합성 저해효과는 B16-F10 마우스 멜라노마 세포를 이용하여 확인하였다. B16-F10 마우스 멜라노마 세포를 12-웰 플레이트에 1×105 cells/㎖이 되도록 접종하여 24시간 동안 배양한 후, 각 웰에 α-MSH(melanocyte-stimulating hormone)를 처리하여 멜라닌 생합성을 유도한 뒤 알부틴(arbutin), 제조예 1의 농도별(25 및 50㎍/㎖) 단풍취 추출물 또는 제조예 1의 농도별(25 및 50㎍/㎖) 단풍취 식초를 각각 48시간 동안 처리하였다. 48시간 후 배지를 제거하고 인산완충액(phosphatate buffer saline, PBS)으로 2회 세척한 후 부착된 세포를 원심분리하여 펠렛(pellet)을 얻었다. 침전된 멜라노마 세포에 1N 수산화나트륨(NaOH)에 DMSO가 10%가 되도록 만든 용액 200㎕를 가하고, 60℃에서 1시간 동안 용해하였으며, 405㎚에서 흡광도를 측정하였다. The melanin biosynthesis inhibitory effect of the ethanol extract, the ethanolic acetic acid fermented vinegar, and the acetic acid fermented vinegar of Example 1 was confirmed using B16-F10 mouse melanoma cells. B16-F10 mouse melanoma cells were inoculated on a 12-well plate at a density of 1 x 10 5 cells / ml and cultured for 24 hours. Melanocyte-stimulating hormone (α-MSH) (25 and 50 占 퐂 / ml), or the concentration of Preparation Example 1 (25 and 50 占 퐂 / ml), were treated for 48 hours, respectively. After 48 hours, the medium was removed and the cells were washed twice with phosphate buffered saline (PBS), and the adhered cells were centrifuged to obtain a pellet. To the precipitated melanoma cells, 200 μl of a solution prepared by adding 1 N sodium hydroxide (NaOH) to 10% DMSO was added and dissolved at 60 ° C for 1 hour. Absorbance was measured at 405 nm.
그 결과, 도 1(b)에 나타난 바와 같이 단풍취 물 추출물 25 및 50㎍/㎖와 에탄올 추출물 25㎍/㎖를 제외한 모든 처리구에서 멜라닌 생합성 억제효과를 확인하였으며, 물 또는 에탄올 추출물에 비해 초산 발효 식초의 멜라닌 생합성 억제효과가 우수하였고, 특히, 에탄올 초산 발효 식초의 멜라닌 생합성 억제효과가 가장 우수하였다. As a result, as shown in Fig. 1 (b), melanin biosynthesis inhibitory effect was confirmed in all the treatments except for 25 and 50 μg / ml of the single-bladder water extract and 25 μg / ml of the ethanol extract, and compared with water or ethanol extract, The effect of inhibiting the melanin biosynthesis of ethanolic acetic acid fermented vinegar was most excellent.
실시예Example 3. 3. 단풍취A single blow 추출물 및 식초의 Of extract and vinegar NONO (( nitricnitric oxideoxide ) 생성 억제효과 확인) Production inhibitory effect
제조예 1의 단풍취 물 추출물, 물 초산 발효 식초, 에탄올 추출물, 에탄올 초산 발효 식초의 항염효과를 검증하기 위해 마우스 대식세포주인 RAW 264.7 세포를 96-웰 플레이트에 1×106 cells/㎖가 되도록 접종하고, 37℃ 온도와 5% CO2가 유지되는 배양기에서 24시간 동안 배양하였다. 이후 각 웰에 제조예 1의 농도별(25 및 50㎍/㎖) 단풍취 추출물 또는 식초를 1시간 동안 처리하고, 그 후 1㎍/㎖의 LPS를 처리하여 24시간 배양하였다. 배양 후 배양액의 상징액을 얻고, 상징액과 그리스(griess) 시약을 반응시킨 후, 분광광도계를 이용하여 540㎚ 파장에서 흡광도를 측정하였다. NO 생성율은 LPS 처리군 대비 백분율로 나타내었다. In order to examine the anti-inflammatory effect of the water blotter extract, the water-acetic acid fermentation vinegar, the ethanol extract, and the ethanolic acetic acid fermentation vinegar prepared in Preparation Example 1, RAW 264.7 cells as mouse macrophages were inoculated into 96-well plates at a density of 1 × 10 6 cells / and, 37 ℃ temperature and 5% CO 2 that is maintained And cultured in an incubator for 24 hours. Then, each of the wells was treated with 1 ㎍ / L of LPS and cultured for 24 hours. After incubation, a supernatant of the culture was obtained, and the supernatant was reacted with a griess reagent. Then, the absorbance at 540 nm was measured using a spectrophotometer. The NO production rate was expressed as a percentage of the LPS-treated group.
그 결과, 도 1(c)에 나타난 바와 같이 단풍취 물 추출물을 제외한 모든 처리구에서 NO 생성 억제효과를 확인할 수 있었으며, 물 추출물 및 물 초산 발효 식초에 비해 에탄올 추출물 및 에탄올 초산 발효 식초의 NO 생성 억제효과가 우수하였으며, 특히 에탄올 초산 발효 식초 50㎍/㎖ 처리시 NO 생성 억제효과가 가장 우수하다는 것을 확인하였다. As a result, as shown in Fig. 1 (c), the inhibitory effect of NO production was confirmed in all treatments except for the single-blind water extract. Compared to the water extract and the water acetic acid fermented vinegar, the inhibitory effect of ethanol extract and ethanolic acetic acid fermented vinegar , And it was confirmed that the treatment with ethanol acetic acid fermentation vinegar at 50 ㎍ / ㎖ showed the best inhibitory effect on NO production.
Claims (8)
(b) 상기 단계 (a)에서 세척한 단풍취에 용매를 첨가하여 추출물을 제조하는 단계;
(c) 상기 단계 (b)에서 제조된 단풍취 추출물에 초산균을 접종하여 초산 발효물을 제조하는 단계; 및
(d) 상기 단계 (c)에서 제조된 초산 발효물을 여과하고 숙성시켜 식초를 제조하는 단계;를 포함하는 것을 특징으로 하는 항비만, 항염증 및 피부 미백 효능이 증진된 단풍취 식초의 제조방법.(a) washing the deodorizer;
(b) preparing an extract by adding a solvent to the deodorized leaves collected in step (a);
(c) preparing acetic acid fermented product by inoculating acetic acid to the extract of monoptera produced in step (b); And
(d) filtering and aging the fermented acetic acid produced in step (c) to produce a vinegar.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160095897 | 2016-07-28 | ||
| KR20160095897 | 2016-07-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180013797A true KR20180013797A (en) | 2018-02-07 |
| KR101937331B1 KR101937331B1 (en) | 2019-01-11 |
Family
ID=61204560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170096093A KR101937331B1 (en) | 2016-07-28 | 2017-07-28 | Vinegar with enhanced anti-obesity, anti-inflammatory and skin whitening effect using Mapleleaf ainsliaea and manufacturing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101937331B1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102105897B1 (en) * | 2018-11-20 | 2020-05-04 | 안동대학교 산학협력단 | Skin whitening composition comprising Ainsliaea acerifolia extract produced by ultra high pressure homogenization as effective component |
| KR20210087725A (en) * | 2020-01-03 | 2021-07-13 | 안동대학교 산학협력단 | Composition for anti-obesity comprising Ainsliaea acerifolia extract produced by enzyme treatment and ultra high pressure homogenization as effective component |
| KR20220003893A (en) * | 2020-07-02 | 2022-01-11 | 충남대학교산학협력단 | Composition for preventing, improving or treating prostate disease comprising extract of Ainsliaea acerifolia as effective component |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102158337B1 (en) * | 2019-03-13 | 2020-09-25 | 안동대학교 산학협력단 | Composition for preventing, ameliorating or treating fatty liver disease comprising vinegar of Kalopanax septemlobus as effective component |
| KR102569246B1 (en) | 2021-11-03 | 2023-08-21 | 동의대학교 산학협력단 | Composition for skin whitening and wrinkle improvement containing saussurea neoserrata extract |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020034102A (en) * | 2002-02-04 | 2002-05-08 | 손영석 | Manufacturing method of vinegar containing substance to become medicine |
| KR101056779B1 (en) * | 2008-12-19 | 2011-08-16 | 영농조합법인 선인장연구회 | Brewed vinegar prepared using the cactus extract and the source containing the brewed vinegar and a method for producing the same |
| KR101738753B1 (en) * | 2015-06-24 | 2017-06-09 | 경상북도(관련부서:경상북도산림자원개발원) | Healthful composition using Mapleleaf Aisnsliaea extracts, and funtional drinks comprising the same |
-
2017
- 2017-07-28 KR KR1020170096093A patent/KR101937331B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020034102A (en) * | 2002-02-04 | 2002-05-08 | 손영석 | Manufacturing method of vinegar containing substance to become medicine |
| KR101056779B1 (en) * | 2008-12-19 | 2011-08-16 | 영농조합법인 선인장연구회 | Brewed vinegar prepared using the cactus extract and the source containing the brewed vinegar and a method for producing the same |
| KR101738753B1 (en) * | 2015-06-24 | 2017-06-09 | 경상북도(관련부서:경상북도산림자원개발원) | Healthful composition using Mapleleaf Aisnsliaea extracts, and funtional drinks comprising the same |
Non-Patent Citations (2)
| Title |
|---|
| 김유정 등, ‘Anti-inflammatory activity of Ethanol Extracts from Ainsliaea acerifolia’, 한국식품영양과학회 산업심포지움발표집 pp.423(2015.08.31) 1부. * |
| 이은우 등, ‘Antioxidant and α-glucosidase inhibitory effects of ethanolic extreact of Ainsliaea acerifolia and organic solvent-soluble fractions’, 한국식품저장유통학회 vol.22 no.2 pp.275-280(2015.04.30.) 1부. * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102105897B1 (en) * | 2018-11-20 | 2020-05-04 | 안동대학교 산학협력단 | Skin whitening composition comprising Ainsliaea acerifolia extract produced by ultra high pressure homogenization as effective component |
| KR20210087725A (en) * | 2020-01-03 | 2021-07-13 | 안동대학교 산학협력단 | Composition for anti-obesity comprising Ainsliaea acerifolia extract produced by enzyme treatment and ultra high pressure homogenization as effective component |
| KR20220003893A (en) * | 2020-07-02 | 2022-01-11 | 충남대학교산학협력단 | Composition for preventing, improving or treating prostate disease comprising extract of Ainsliaea acerifolia as effective component |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101937331B1 (en) | 2019-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101937331B1 (en) | Vinegar with enhanced anti-obesity, anti-inflammatory and skin whitening effect using Mapleleaf ainsliaea and manufacturing method thereof | |
| Wang et al. | Extraction, purification, structural characteristics, biological activities, and application of the polysaccharides from Nelumbo nucifera Gaertn.(lotus): A review | |
| KR102149177B1 (en) | Vinegar with enhanced skin whitening effect using Aster scaber and Ficus carica and production method thereof | |
| KR20200125155A (en) | Composition for improvementing, preventing or treating obesity and metabolic diseases comprising fractions or extract of radish leave | |
| KR102180223B1 (en) | Anti-obesity composition comprising extract of Sargassum horneri | |
| KR102263698B1 (en) | A mixture of Lactobacillus plantarum LRCC5195 and isomaltooligosaccharide having ameliorating or improving atopic dermatitis | |
| KR20180014272A (en) | Composition for skin whitening or anti-inflammatory comprising Zizyphus jujube seed extract as effective component | |
| KR101307501B1 (en) | Composition for preventing or treating immune disease comprising dandelion water extract as an active ingredient | |
| CN102511582B (en) | Rosa roxburghii tea bag and preparation method thereof | |
| KR100874778B1 (en) | Composition for the prevention and treatment of menopausal diseases comprising fermented Cheonggukjang extract | |
| KR101943976B1 (en) | Composition for skin whitening comprising Capsicum annuum seed extract as effective component | |
| CN104403913A (en) | Lipid-lowering and weight-reducing persimmon vinegar | |
| KR20230010167A (en) | Composion of fermented oriental herb, method of manufacturing the same and use of the same | |
| KR20230054129A (en) | Antioxidant, skin whitening and skin wrinkle improvement composition | |
| KR101858118B1 (en) | Composition for skin whitening comprising fermented Geomgangsong as effective component | |
| KR102552886B1 (en) | Composition for preventing and improving obesity, and functional food containing the same | |
| KR20200125156A (en) | Composition for improvementing, preventing or treating obesity and metabolic diseases comprising fractions or extract of pepper leave | |
| KR102514704B1 (en) | Manufacturing method of food compositon comprising plant extracts for inhibiting obesity | |
| JP7505680B2 (en) | Composition for enhancing filaggrin and/or involucrin gene expression, and composition for stimulating fibroblasts | |
| KR101963630B1 (en) | Anti-inflammatory composition comprising pepper leaf extract produced by enzyme treatment as effective component | |
| KR102216618B1 (en) | Fermentation method of lactic acid bacteria using artichoke and its use | |
| KR102153516B1 (en) | Composition for preventing, treating or improving obesity comprising bioconverted fruit extract of Akebia quinata | |
| TW202130281A (en) | Novel use of steviol | |
| KR20230153536A (en) | Anti-inflammatory composition comprising biorenovation extract of Lycium chinense sprout as effective component | |
| KR20230115516A (en) | Composition for Anti-inflammation Using an Extract of Sargassum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) |